Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-05-15 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2023年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the "2023 Annual General Meeting (AGM) materials" for Hangzhou Anxu Biotechnology Co., Ltd. It includes detailed agenda items for the 2023 AGM, such as the 2023 Board of Directors work report, 2023 Supervisory Board work report, 2023 Annual Report and its summary, 2023 Financial Final Accounts Report, profit distribution plan, amendments to company articles, reappointment of audit institutions, and remuneration plans. The document also contains meeting instructions, voting procedures, and detailed reports related to the AGM. The content is consistent with materials prepared and distributed for an Annual General Meeting, including reports and proposals to be discussed and voted on at the meeting. It is not the annual report itself but the meeting materials for the AGM. Therefore, the correct classification is AGM Information (AGM-R). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice but the actual AGM materials.
2024-05-15 Chinese
安旭生物关于召开2023年度暨2024年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a performance explanation meeting (业绩说明会) for the 2023 annual and 2024 first quarter results. It provides details on the meeting time, location, format, and participation instructions. It references that the 2023 annual report and 2024 first quarter report have already been published on April 30, 2024, but this document itself is not the report or transcript of the meeting. The document is short (1537 characters) and serves as a notice for an upcoming investor presentation event rather than containing financial data or detailed analysis. Therefore, it fits best as an Investor Presentation (IP) announcement or a meeting notice. Given the detailed description of the meeting and its investor focus, the classification as Investor Presentation (IP) is appropriate with high confidence.
2024-05-08 Chinese
2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度会计师事务所履职情况评估报告' which translates to '2023 Annual Evaluation Report on the Performance of the Accounting Firm'. It details the change of the company's auditor, the auditor's qualifications, the audit process, and the auditor's opinion on the 2023 financial statements. The document includes an audit opinion stating a standard unqualified opinion was issued. However, the document is only 2076 characters long and primarily focuses on the evaluation of the auditor's performance rather than presenting the full audit report or detailed financial statements. It does not contain the full annual report or detailed financial data but rather an assessment of the auditor's work and the audit process. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report discussing audit procedures, auditor changes, and audit opinions without being the full annual report itself. FY 2023
2024-04-29 Chinese
第二届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Hangzhou Anxu Biotechnology Co., Ltd. It discusses the approval of various reports and proposals related to the company's 2023 Annual Report, 2023 Annual Financial Statements, 2023 Profit Distribution Plan, 2023 Fundraising Usage Report, 2024 Auditor Appointment, 2023 Internal Control Evaluation Report, 2023 Asset Impairment Provision, and the 2024 First Quarter Report. The document repeatedly states that these reports have been reviewed and approved by the Supervisory Board and will be submitted to the 2023 Annual General Meeting for further approval. It also references that the full reports are disclosed separately on the Shanghai Stock Exchange website. The document itself is only 3354 characters long and primarily serves as an announcement of the Supervisory Board's resolutions rather than containing the full reports or detailed financial data. According to the "Menu vs Meal" rule, this document is an announcement of resolutions and approvals related to annual and quarterly reports, not the reports themselves. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not contain the full report content.
2024-04-29 Chinese
董事会关于独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence self-assessment of independent directors for the year 2023. It references regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The content focuses on governance and compliance related to board members' independence, without financial data or broader management discussion. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is short and it is not an announcement of a report but the report itself. Therefore, the classification is CGR with high confidence.
2024-04-29 Chinese
2023年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Hangzhou Anxu Biotechnology Co., Ltd. regarding the 2023 annual status of raised funds (募集资金) — their deposit and actual usage. It references regulatory guidelines specifically about the management and use of raised funds for listed companies, including compliance with China Securities Regulatory Commission and Shanghai Stock Exchange rules. The document includes detailed financial figures about the amount raised, usage, balances, and investment of idle funds, as well as management and supervisory agreements. It also contains auditor and sponsor institution opinions on the compliance and accuracy of the report. The document is lengthy (over 10,000 characters) and contains substantive financial data and analysis related to capital raised and its deployment during the fiscal year 2023. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report publication, nor a general regulatory filing, nor an annual or interim report. Therefore, the correct classification is CAP with high confidence.
2024-04-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.